According to the literature, PPAR agonists are suitable drug targets for treating highly prevalent metabolic diseases, such as type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.